5DMJ
| |
7P3I
| Crystal structure of human CD40/TNFRSF5 in complex with the anti-CD40 DARPin protein | Descriptor: | Darpin, SODIUM ION, Tumor necrosis factor receptor superfamily member 5 | Authors: | Malvezzi, F, Mangold, S, Hospodarsch, T, Reichen, C, Iss, C, Lammens, A, Krapp, S, Domke, C. | Deposit date: | 2021-07-07 | Release date: | 2022-04-06 | Last modified: | 2024-11-13 | Method: | X-RAY DIFFRACTION (2.29 Å) | Cite: | A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression. Cancer Immunol Res, 10, 2022
|
|
4OD2
| |
2UWI
| Structure of CrmE, a poxvirus TNF receptor | Descriptor: | CRME PROTEIN | Authors: | Graham, S.C, Bahar, M.W, Abrescia, N.G, Smith, G.L, Stuart, D.I, Grimes, J.M. | Deposit date: | 2007-03-22 | Release date: | 2007-07-10 | Last modified: | 2019-05-15 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | Structure of Crme, a Virus-Encoded Tumour Necrosis Factor Receptor. J.Mol.Biol., 372, 2007
|
|
7D4B
| Crystal structure of 4-1BB in complex with a VHH | Descriptor: | 1,2-ETHANEDIOL, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, CHLORIDE ION, ... | Authors: | Wang, C. | Deposit date: | 2020-09-23 | Release date: | 2021-07-14 | Last modified: | 2024-10-16 | Method: | X-RAY DIFFRACTION (3.14 Å) | Cite: | Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer. J Immunother Cancer, 9, 2021
|
|
5IHL
| |
8AG1
| Crystal structure of a novel OX40 antibody | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Novel OX40 antibody heavy chain, Novel OX40 antibody light chain, ... | Authors: | Gao, H, Zhou, A. | Deposit date: | 2022-07-19 | Release date: | 2023-07-19 | Last modified: | 2024-11-06 | Method: | X-RAY DIFFRACTION (3.303 Å) | Cite: | Structural Basis of a Novel Agonistic Anti-OX40 Antibody. Biomolecules, 12, 2022
|
|
6Y8K
| Crystal structure of CD137 in complex with the cyclic peptide BCY10916 | Descriptor: | 1,1',1''-(1,3,5-triazinane-1,3,5-triyl)tripropan-1-one, 1,2-ETHANEDIOL, ACETATE ION, ... | Authors: | Upadhyaya, P, Kublin, J, Dods, R, Kristensson, J, Lahdenranta, J, Kleyman, M, Repash, E, Ma, J, Mudd, G, Van Rietschoten, K, Haines, E, Harrison, H, Beswick, P, Chen, L, McDonnell, K, Battula, S, Hurov, K, Keen, N. | Deposit date: | 2020-03-05 | Release date: | 2021-02-03 | Last modified: | 2024-11-06 | Method: | X-RAY DIFFRACTION (2.011 Å) | Cite: | Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist. J Immunother Cancer, 9, 2021
|
|
6FAX
| Complex of Human CD40 Ectodomain with Lob 7.4 Fab | Descriptor: | Lob 7.4 heavy chain, Lob 7.4 light chain, Tumor necrosis factor receptor superfamily member 5 | Authors: | Orr, C.M, Tews, I, Pearson, A.R. | Deposit date: | 2017-12-18 | Release date: | 2018-02-07 | Last modified: | 2024-11-06 | Method: | X-RAY DIFFRACTION (2.99 Å) | Cite: | Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies. Cancer Cell, 33, 2018
|
|
5DMI
| |
6T3J
| Dual Epitope Targeting by Anti-DR5 Antibodies | Descriptor: | IgG1-hDR5-01-Heavy Chain, IgG1-hDR5-01-Light Chain, IgG1-hDR5-05-Heavy Chain, ... | Authors: | Tauchert, M.J, Augustin, M, Krapp, S, Overdijk, M.B, Breij, E.C.W, Hibbert, R.G. | Deposit date: | 2019-10-11 | Release date: | 2020-09-16 | Last modified: | 2024-10-16 | Method: | X-RAY DIFFRACTION (3.05 Å) | Cite: | Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism. Mol.Cancer Ther., 19, 2020
|
|
1NCF
| |
2HEY
| Crystal structure of murine OX40L bound to human OX40 | Descriptor: | SULFATE ION, Tumor necrosis factor ligand superfamily member 4, Tumor necrosis factor receptor superfamily member 4 | Authors: | Hymowitz, S.G. | Deposit date: | 2006-06-22 | Release date: | 2006-08-29 | Last modified: | 2011-07-13 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | The Crystal Structure of the Costimulatory OX40-OX40L Complex. Structure, 14, 2006
|
|
8OZ3
| Crystal structure of scFv ATOR 1017 bound to human 4-1BB | Descriptor: | Single chain Fv, Tumor necrosis factor receptor superfamily member 9 | Authors: | Hakansson, M, Von Schantz, L, Rose, N. | Deposit date: | 2023-05-08 | Release date: | 2024-03-13 | Last modified: | 2024-11-06 | Method: | X-RAY DIFFRACTION (3.1 Å) | Cite: | ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1. Cancer Immunol.Immunother., 72, 2023
|
|
8P6Q
| Racemic structure of TNFR1 cysteine-rich domain | Descriptor: | D-TNFR-1 CRD2, SULFATE ION, Tumor necrosis factor-binding protein 1 | Authors: | Lander, A.J, Jin, Y, Luk, L.Y.P. | Deposit date: | 2023-05-28 | Release date: | 2024-01-24 | Last modified: | 2024-10-23 | Method: | X-RAY DIFFRACTION (1.4 Å) | Cite: | Deciphering the Synthetic and Refolding Strategy of a Cysteine-Rich Domain in the Tumor Necrosis Factor Receptor (TNF-R) for Racemic Crystallography Analysis and d-Peptide Ligand Discovery. Acs Bio Med Chem Au, 4, 2024
|
|
2HEV
| Crystal structure of the complex between OX40L and OX40 | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Tumor necrosis factor ligand superfamily member 4, Tumor necrosis factor receptor superfamily member 4 | Authors: | Hymowitz, S.G, Compaan, D.M. | Deposit date: | 2006-06-22 | Release date: | 2006-08-29 | Last modified: | 2024-10-30 | Method: | X-RAY DIFFRACTION (2.41 Å) | Cite: | The Crystal Structure of the Costimulatory OX40-OX40L Complex. Structure, 14, 2006
|
|
8YX9
| CD40 in complex with Dacetuzumab Fab | Descriptor: | Dacetuzumab, Heavy chain, light chain, ... | Authors: | Caaveiro, J.M.M, Fernandez-Perez, J, Tsumoto, K. | Deposit date: | 2024-04-02 | Release date: | 2024-05-08 | Last modified: | 2024-10-16 | Method: | X-RAY DIFFRACTION (2.8 Å) | Cite: | Crystal structures of human CD40 in complex with monoclonal antibodies dacetuzumab and bleselumab. Biochem.Biophys.Res.Commun., 714, 2024
|
|
8YX1
| CD40 in complex with Bleselumab Fab | Descriptor: | Bleselumab, heavy chain, light chain, ... | Authors: | Caaveiro, J.M.M, Fernandez-Perez, J, Tsumoto, K. | Deposit date: | 2024-04-01 | Release date: | 2024-05-08 | Last modified: | 2024-11-06 | Method: | X-RAY DIFFRACTION (2.7 Å) | Cite: | Crystal structures of human CD40 in complex with monoclonal antibodies dacetuzumab and bleselumab. Biochem.Biophys.Res.Commun., 714, 2024
|
|
7MSJ
| The crystal structure of mouse HVEM | Descriptor: | SULFATE ION, Tumor necrosis factor receptor superfamily member 14 | Authors: | Liu, W, Ramagopal, U, Garrett-Thompson, S.C, Fedorov, E, Bonanno, J.B, Almo, S.C. | Deposit date: | 2021-05-11 | Release date: | 2021-10-27 | Last modified: | 2024-10-23 | Method: | X-RAY DIFFRACTION (2.1 Å) | Cite: | HVEM structures and mutants reveal distinct functions of binding to LIGHT and BTLA/CD160. J.Exp.Med., 218, 2021
|
|
8DS5
| X-ray structure of the MK5890 Fab - CD27 antibody-antigen complex | Descriptor: | CADMIUM ION, CD27 antigen, MK-5890 Fab heavy chain, ... | Authors: | Fischmann, T.O. | Deposit date: | 2022-07-21 | Release date: | 2022-09-28 | Last modified: | 2024-10-30 | Method: | X-RAY DIFFRACTION (1.926 Å) | Cite: | Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy. J Immunother Cancer, 10, 2022
|
|
3WVT
| |
1FT4
| |
8DPX
| Preligand association structure of DR5 | Descriptor: | Tumor necrosis factor receptor superfamily member 10B | Authors: | Du, G, Zhao, L, Chou, J.J. | Deposit date: | 2022-07-17 | Release date: | 2023-02-15 | Last modified: | 2024-11-13 | Method: | SOLUTION NMR | Cite: | Autoinhibitory structure of preligand association state implicates a new strategy to attain effective DR5 receptor activation. Cell Res., 33, 2023
|
|
2H9G
| |
7YXU
| Crystal structure of agonistic antibody 1618 fab domain bound to human 4-1BB. | Descriptor: | MANGANESE (II) ION, Tumor necrosis factor receptor superfamily member 9, heavy chain of Fab, ... | Authors: | Hakansson, M, Rose, N, Petersson, J, Enell Smith, K, Thorolfsson, M, von Schantz, L. | Deposit date: | 2022-02-16 | Release date: | 2023-01-25 | Last modified: | 2024-02-07 | Method: | X-RAY DIFFRACTION (2.31 Å) | Cite: | The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies. Mol.Cancer Ther., 22, 2023
|
|